| Entry |
|
|---|
| Name |
Candesartan cilexetil (JP18/USP);
Atacand (TN) |
|---|
| Product |
|
|---|
| Generic |
CANDESARTAN (Macleods Pharmaceuticals Limited), CANDESARTAN CILEXETIL (ANI Pharmaceuticals), CANDESARTAN CILEXETIL (Alembic Pharmaceuticals Limited), CANDESARTAN CILEXETIL (Alembic Pharmaceuticals Limited), CANDESARTAN CILEXETIL (Alembic Pharmaceuticals), CANDESARTAN CILEXETIL (Alembic Pharmaceuticals), CANDESARTAN CILEXETIL (American Health Packaging), CANDESARTAN CILEXETIL (Bryant Ranch Prepack), CANDESARTAN CILEXETIL (Bryant Ranch Prepack), CANDESARTAN CILEXETIL (Bryant Ranch Prepack), CANDESARTAN CILEXETIL (Bryant Ranch Prepack), CANDESARTAN CILEXETIL (Bryant Ranch Prepack), CANDESARTAN CILEXETIL (Golden State Medical Supply), CANDESARTAN CILEXETIL (Mylan Pharmaceuticals), CANDESARTAN CILEXETIL (Par Pharmaceutical), CANDESARTAN CILEXETIL (Zydus Lifesciences Limited), CANDESARTAN CILEXETIL (Zydus Pharmaceuticals USA) |
|---|
| Formula |
C33H34N6O6
|
|---|
| Exact mass |
610.2540
|
|---|
| Mol weight |
610.66
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01925 Renin-angiotensin system inhibitor
DG01495 Angiotensin II receptor antagonist
DG03231 Antihypertensive
DG01495 Angiotensin II receptor antagonist
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG02970 CES substrate
|
|---|
| Remark |
| Product (DG00350): | D00626<JP/US> |
| Product (mixture): | D07569<JP> D09196<JP/US> |
|
|---|
| Efficacy |
Antihypertensive, Angiotensin II receptor antagonist |
|---|
| Disease |
|
|---|
| Comment |
Active form of prodrug: Candesartan [DR: D00522]
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04261 | Adrenergic signaling in cardiomyocytes |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07229 | Angiotensin receptor and endothelin receptor antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09C ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09CA Angiotensin II receptor blockers (ARBs), plain
C09CA06 Candesartan
D00626 Candesartan cilexetil (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Angiotensin II Receptor Antagonists
Candesartan
D00626 Candesartan cilexetil (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
214 Antihypertensives
2149 Others
D00626 Candesartan cilexetil (JP18/USP)
217 Vasodilators
2179 Others
D00626 Candesartan cilexetil (JP18/USP)
Drug groups [BR:br08330]
Cardiovascular agent
DG01925 Renin-angiotensin system inhibitor
DG01495 Angiotensin II receptor antagonist
DG00350 Candesartan
D00626 Candesartan cilexetil
DG03231 Antihypertensive
DG01495 Angiotensin II receptor antagonist
DG00350 Candesartan
D00626 Candesartan cilexetil
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG00350 Candesartan
D00626 Candesartan cilexetil
DG02970 CES substrate
D00626 Candesartan cilexetil
Drug classes [BR:br08332]
Cardiovascular agent
DG01495 Angiotensin II receptor antagonist
D00626 Candesartan cilexetil
DG03231 Antihypertensive
D00626 Candesartan cilexetil
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Angiotensin
AGTR1
D00626 Candesartan cilexetil (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00626 Candesartan cilexetil
D00626 Candesartan cilexetil tablets
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00626
Prodrugs [br08324.html]
D00626
Drug groups [BR:br08330]
Cardiovascular agent
DG01925 Renin-angiotensin system inhibitor
DG01495 Angiotensin II receptor antagonist
DG00350 Candesartan
DG03231 Antihypertensive
DG01495 Angiotensin II receptor antagonist
DG00350 Candesartan
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG00350 Candesartan
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 45
1 C8y C 22.5038 -13.1468
2 N4y N 22.0601 -11.8210
3 C8y C 23.8997 -13.1525
4 C8y C 21.8032 -14.3557
5 C8y C 23.1989 -10.9859
6 C1b C 20.8336 -11.1319
7 N5x N 24.3377 -11.8210
8 C8x C 24.5946 -14.3615
9 C8x C 22.4981 -15.5646
10 C7a C 21.0907 -15.5587
11 O2a O 23.1989 -9.5843
12 C8y C 19.6306 -11.8561
13 C8x C 23.8938 -15.5704
14 O7a O 19.6890 -15.5470
15 O6a O 21.7739 -16.7735
16 C1b C 24.4135 -8.8836
17 C8x C 18.3983 -11.1729
18 C8x C 19.6597 -13.2343
19 C1c C 18.9882 -16.7501
20 C1a C 24.4135 -7.4820
21 C8x C 17.1953 -11.8971
22 C8x C 18.4451 -13.9819
23 O7a O 17.5923 -16.7501
24 C1a C 19.6773 -17.9590
25 C8y C 17.2302 -13.2987
26 C7a C 16.8974 -17.9531
27 C8y C 16.0215 -14.0170
28 O7a O 15.5075 -17.9531
29 O6a O 17.5923 -19.1680
30 C8y C 14.7892 -13.3395
31 C8x C 16.0447 -15.4186
32 C1y C 14.8067 -19.1620
33 C8y C 14.7658 -11.9321
34 C8x C 13.5920 -14.0578
35 C8x C 14.8417 -16.1428
36 C1x C 13.4167 -19.1620
37 C1x C 15.5075 -20.3769
38 N4x N 13.6328 -11.1261
39 N5x N 15.8987 -11.0853
40 C8x C 13.6211 -15.4654
41 C1x C 12.7159 -20.3769
42 C1x C 14.8126 -21.5858
43 N5x N 14.0416 -9.7829
44 N5x N 15.4433 -9.7595
45 C1x C 13.4167 -21.5858
BOND 50
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 3 8 1
8 4 9 2
9 4 10 1
10 5 11 1
11 6 12 1
12 8 13 2
13 10 14 1
14 10 15 2
15 11 16 1
16 12 17 1
17 12 18 2
18 14 19 1
19 16 20 1
20 17 21 2
21 18 22 1
22 19 23 1
23 19 24 1
24 21 25 1
25 23 26 1
26 25 27 1
27 26 28 1
28 26 29 2
29 27 30 1
30 27 31 2
31 28 32 1
32 30 33 1
33 30 34 2
34 31 35 1
35 32 36 1
36 32 37 1
37 33 38 1
38 33 39 2
39 34 40 1
40 36 41 1
41 37 42 1
42 38 43 1
43 39 44 1
44 41 45 1
45 5 7 2
46 9 13 1
47 22 25 2
48 35 40 2
49 42 45 1
50 43 44 2
|
|---|
